MiniMed Group Inc (NASDAQ:MMED) Given Average Recommendation of “Moderate Buy” by Brokerages

Posted by Amy Steele on Jun 21st, 2026

MiniMed Group Inc (NASDAQ:MMED – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $21.3333.

MMED has been the topic of a number of recent analyst reports. Weiss Ratings initiated coverage on MiniMed Group in a research report on Wednesday, May 27th. They set a “sell (d)” rating on the stock. Benchmark reiterated a “buy” rating on shares of MiniMed Group in a research report on Thursday, June 4th. The Goldman Sachs Group initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $24.00 target price on the stock. Wall Street Zen upgraded MiniMed Group to a “hold” rating in a research report on Saturday, March 14th. Finally, Mizuho initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set an “outperform” rating and a $21.00 target price on the stock.

Get Our Latest Research Report on MMED

MiniMed Group Stock Performance

Shares of NASDAQ MMED opened at $14.77 on Friday. MiniMed Group has a 12 month low of $10.65 and a 12 month high of $20.48. The stock’s 50 day moving average price is $13.02.

MiniMed Group (NASDAQ:MMED – Get Free Report) last issued its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The firm had revenue of $837.00 million for the quarter. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year.

MiniMed Group Company Profile

(Get Free Report)

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.